Nrf2 exerts cell-autonomous antifibrotic effects: compromised function in systemic sclerosis and therapeutic rescue with a novel heterocyclic chalcone derivative
- 1 May 2017
- journal article
- Published by Elsevier in Translational Research
- Vol. 183, 71-86.e1
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (AR-42309, AR-066418, AR-065800, OD-010945, CA-060553)
This publication has 55 references indexed in Scilit:
- Nuclear Factor–Erythroid-2–Related Factor 2 in Aging and Lung FibrosisThe American Journal of Pathology, 2016
- Metabolomics analysis reveals the association between lipid abnormalities and oxidative stress, inflammation, fibrosis and Nrf2 dysfunction in aristolochic acid-induced nephropathyScientific Reports, 2015
- Experimentally-Derived Fibroblast Gene Signatures Identify Molecular Pathways Associated with Distinct Subsets of Systemic Sclerosis Patients in Three Independent CohortsPLOS ONE, 2015
- MicroRNA-200a controls Nrf2 activation by target Keap1 in hepatic stellate cell proliferation and fibrosisCellular Signalling, 2014
- A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responsesAnnals of the Rheumatic Diseases, 2014
- Role of Nrf2 in Oxidative Stress and ToxicityAnnual Review of Pharmacology and Toxicology, 2013
- Nuclear Factor Erythroid 2-Related Factor 2 Nuclear Translocation Induces Myofibroblastic Dedifferentiation in Idiopathic Pulmonary FibrosisAntioxidants & Redox Signaling, 2013
- Synthetic Oleanane Triterpenoids: Multifunctional Drugs with a Broad Range of Applications for Prevention and Treatment of Chronic DiseasePharmacological Reviews, 2012
- Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunitiesNature Reviews Rheumatology, 2011
- Oxidative stress in health and disease: The therapeutic potential of Nrf2 activationMolecular Aspects of Medicine, 2011